These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31793023)

  • 1. Adverse reactions to meglumine antimoniate in Brazilian inpatients with visceral leishmaniases: A case series.
    Serbate Borges Portela Á; Margotto Bertollo C; da Silva Praxedes MF; Silva Brasileiro SA; Moreira Reis AM; Parreiras Martins MA
    J Clin Pharm Ther; 2020 Jun; 45(3):573-576. PubMed ID: 31793023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
    Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
    Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
    AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil.
    de Carvalho IPSF; Peixoto HM; Romero GAS; de Oliveira MRF
    Trop Med Int Health; 2019 Sep; 24(9):1064-1077. PubMed ID: 31278808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of visceral leishmaniasis in children in the Central-West Region of Brazil.
    Brustoloni YM; Cunha RV; Cônsolo LZ; Oliveira AL; Dorval ME; Oshiro ET
    Infection; 2010 Aug; 38(4):261-7. PubMed ID: 20508967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil.
    Oliveira AL; Brustoloni YM; Fernandes TD; Dorval ME; Cunha RV; Bóia MN
    Trop Doct; 2009 Jul; 39(3):180-2. PubMed ID: 19535762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
    Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
    Kuyucu N; Kara C; Bakirtaç A; Teziç T
    Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Combination Therapy with Liposomal Amphotericin B, N-Methyl Meglumine Antimoniate, and Pentamidine Isethionate for Disseminated Visceral Leishmaniasis in a Splenectomized Adult Patient.
    Vechi HT; Sousa ASV; Cunha MAD; Shaw JJ; Luz KG
    Am J Trop Med Hyg; 2020 Feb; 102(2):268-273. PubMed ID: 31872796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
    Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
    Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV.
    Laguna F; López-Vélez R; Soriano V; Montilla P; Alvar J; González-Lahoz JM
    J Infect; 1994 May; 28(3):255-9. PubMed ID: 8089514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
    Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate.
    Utili R; Rambaldi A; Tripodi MF; Andreana A
    Infection; 1995; 23(3):182-3. PubMed ID: 7499009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The renal transplant patient with visceral leishmaniasis who could not tolerate meglumine antimoniate-cure with ketoconazole and allopurinol.
    Hueso M; Bover J; Serón D; Gil-Vernet S; Rufí G; Alsina J; Grinyó JM
    Nephrol Dial Transplant; 1999 Dec; 14(12):2941-3. PubMed ID: 10570102
    [No Abstract]   [Full Text] [Related]  

  • 15. Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions.
    Cataldo JI; Conceição-Silva F; Antônio LF; Schubach AO; Marzochi MCA; Valete-Rosalino CM; Pimentel MIF; Lyra MR; Oliveira RVC; Barros JHDS; Pacheco RDS; Madeira MF
    Rev Soc Bras Med Trop; 2018; 51(6):769-780. PubMed ID: 30517530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis.
    Kato KC; de Morais-Teixeira E; Islam A; Leite MF; Demicheli C; de Castro WV; Corrêa-Junior JD; Rabello A; Frézard F
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of three chemotherapeutic schemes with meglumine antimoniate in the treatment of visceral leishmaniasis in the State of Pará, Brazil.
    Marsden PD
    Rev Inst Med Trop Sao Paulo; 1993; 35(6):589. PubMed ID: 7997767
    [No Abstract]   [Full Text] [Related]  

  • 19. Relapse in Ethiopian visceral leishmaniasis (VL) patients after therapy with pentavalent antimonials: a ten year observation.
    Berhe N; Ali A; Hailu A; Yeneneh H
    Acta Trop; 1994 Jun; 57(1):83-90. PubMed ID: 7942358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy.
    di Martino L; Mantovani MP; Gradoni L; Gramiccia M; Guandalini S
    Trans R Soc Trop Med Hyg; 1990; 84(4):534-5. PubMed ID: 2091347
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.